Write in a clean editor, then format for Journal of Microbiology Immunology and Infection in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Journal of Microbiology Immunology and Infection is a peer-reviewed journal published by Elsevier, covering Antibiotic Resistance in Bacteria, Antibiotic Use and Resistance, Antimicrobial Resistance in Staphylococcus.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Journal of Microbiology Immunology and Infection 12 (2023) 45–58.
Formats any DOI in Journal of Microbiology Immunology and Infection style. No sign-up. |
| Publishes research in | Antibiotic Resistance in Bacteria Antibiotic Use and Resistance Antimicrobial Resistance in Staphylococcus Pneumonia and Respiratory Infections Nosocomial Infections in ICU |
| ISSN | 1684-1182 |
| Citation impact (2-yr) | 3.11 |
| h-index | 88 |
| i10-index | 1,242 |
| Total citations | 52,512 |
| Article processing charge | $1,000 |
| Open access | Yes |
| Top institutions publishing here | National Taiwan University Hospital |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
COVID-19 is a novel coronavirus with an outbreak of unusual viral pneumonia in Wuhan, China, and then pandemic. Based on its phylogenetic relationships and genomic structures the COVID-19 belongs to genera Betacoronavirus. Human Betacoronaviruses (SARS-CoV-2, SARS-CoV, and MERS-CoV) have many similarities, but also have differences in their genomic and phenotypic structure that can influence their…
Since the emergence of coronavirus disease 2019 (COVID-19) (formerly known as the 2019 novel coronavirus [2019-nCoV]) in Wuhan, China in December 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), more than 75,000 cases have been reported in 32 countries/regions, resulting in more than 2000 deaths worldwide. Despite the fact that most…
COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019. An extremely high potential for dissemination resulted in the global coronavirus disease 2019 (COVID-19) pandemic in 2020. Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in clinical treatment…
